Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Signs Of Change? Lilly, Merck, Janssen Report Slowing List Price Growth In 2018

Executive Summary

Annual transparency reports from the three firms show US price increases continued, though less aggressively, and net prices declined for Lilly and Janssen.

You may also be interested in...



Rhetoric Doesn't Square With Reality, Sanofi Drug Pricing Report Says

Sanofi said the aggregate US net price of its drugs declined by 11.1% in 2019, while list prices increased 2.9%.

Lilly Says Volume Growth Strategy, Launches Working Despite Price Pressures

Trulicity, Taltz grew in the first quarter, but below analyst consensus estimates. Company points to price decreases as holding down growth.

Basaglar Saved Medicaid Millions, Highlighting Benefits Of Competition, JAMA Analysis Shows

Researchers analyzed usage rates, market share and reimbursement information for the long-acting insulins Lantus and Basaglar to determine the impact from the launch of Lilly’s long-acting Basaglar.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124963

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel